Replimune Group, Inc. Form 8-K Summary
Business Context and Reporting Period
Replimune Group, Inc. filed a Current Report on Form 8-K dated June 3, 2022, reporting an event that occurred on May 31, 2022. The filing concerns a change to the company’s board of directors. Replimune is incorporated in Delaware and its common stock trades on Nasdaq under the symbol REPL.
Key Financial Metrics
This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics. It is not a periodic financial report.
Material Changes
- Jason Rhodes resigned as a director effective immediately on May 31, 2022.
- The company stated that the resignation was not due to any dispute or disagreement with the company, management, the Board, or the company’s operations, policies, or practices.
- The filing does not describe a replacement director or any change to board committee assignments.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. It furnishes a June 3, 2022 press release as Exhibit 99.1 regarding Mr. Rhodes’ resignation. The company stated that the related Regulation FD disclosure is not incorporated by reference into other filings unless expressly incorporated and is not deemed filed for purposes of certain liability provisions.
Investor Verification Points
- Confirm the effective date and circumstances of Jason Rhodes’ resignation.
- Review Exhibit 99.1, the June 3, 2022 news release, for any additional commentary.
- Verify whether the company subsequently appointed a replacement director or changed board composition.
- Use the company’s periodic reports for financial condition, liquidity, operating results, and forward-looking guidance, which are not provided in this filing.